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Probiotics are live microorganisms, which when administered in 
adequate amounts confer a health benefit on the host.1 Microbes 
used as probiotics are derived from different genera and species 
and have been studied for a variety of health and disease end-
points. Currently, both yeast (Saccharomyces cerevisiae) and bac-
teria are used as probiotics, including lactic acid bacteria (LAB; 
such as species of Lactobacillus, Streptococcus and Enterococcus), 
Bifidobacterium, Propionibacterium, Bacillus and Escherichia 
coli. They may be naturally occurring microbes (as is the case for 
all used in food), or microbes that have been genetically altered 
for a specific effect. Although genetically modified microbes 
were not specifically addressed in this review (assessment on a 
case-by-case basis is prudent), recommendations for non-recom-
binant microbes, although not sufficient, would be applicable. 
Assessment of safety must take into account the nature of the 
microbe being used, method of administration, level of exposure, 
health status of users and physiological functions they are called 
on to perform.
A context for this discussion is an increasing number of well-
controlled human studies that have tracked adverse incidents 
and have provided long-term follow up on some subject groups, 
providing more data upon which to base safety assessments. 
Furthermore, as usage of probiotics has expanded and meth-
ods to track specific strains have improved, reports of infections 
and other adverse incidents traced to specific probiotics have 
surfaced.
Documented correlations between adverse events and  probiotic 
consumption are few considering their widespread use.2-13 With 
few exceptions, adverse events have been reported primarily in 
patients with underlying medical conditions. However, the 
pathogenesis of opportunistic Lactobacillus infections when they 
do occur is poorly understood. Since microbes used as probiot-
ics are non-pathogenic, it is difficult to identify inherent strain 
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The safety of probiotics is tied to their intended use, which 
includes consideration of potential vulnerability of the 
consumer or patient, dose and duration of consumption, and 
both the manner and frequency of administration. Unique 
to probiotics is that they are alive when administered, and 
unlike other food or drug ingredients, possess the potential for 
infectivity or in situ toxin production. Since numerous types of 
microbes are used as probiotics, safety is also intricately tied 
to the nature of the specific microbe being used. The presence 
of transferable antibiotic resistance genes, which comprises a 
theoretical risk of transfer to a less innocuous member of the 
gut microbial community, must also be considered. Genetic 
stability of the probiotic over time, deleterious metabolic 
activities, and the potential for pathogenicity or toxicogenicity 
must be assessed depending on the characteristics of the 
genus and species of the microbe being used. Immunological 
effects must be considered, especially in certain vulnerable 
populations, including infants with undeveloped immune 
function. A few reports about negative probiotic effects have 
surfaced, the significance of which would be better understood 
with more complete understanding of the mechanisms of 
probiotic interaction with the host and colonizing microbes. 
Use of readily available and low cost genomic sequencing 
technologies to assure the absence of genes of concern is 
advisable for candidate probiotic strains. The field of probiotic 
safety is characterized by the scarcity of studies specifically 
designed to assess safety contrasted with the long history of 
safe use of many of these microbes in foods.
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in Lactobacillus reuteri-reconstituted Lactobacillus-free mice.21 
This single bacterial strain induced epithelial cell activation even 
in the presence of a complex microbiota. Notably, this effect was 
only transient suggesting the initial activation was part of an adap-
tation mechanism. The observed activation of the immune system 
by probiotics could well be due to similar mechanisms preceding 
tolerance towards the respective bacterial strain.
Although the immunocompromised host might benefit the 
most from probiotic supplementation, these populations might 
also be at higher risk for adverse effects such as the development 
of septic conditions due to their reduced capability for microbial 
clearance. This is especially true for probiotic strains that may 
express virulence factors or acquire antibiotic resistance genes via 
horizontal gene transfer.22 As a consequence, probiotics should 
be screened for these possibly harmful characteristics in order 
to ensure their safe use. To date, there are no reports of adverse 
effects of probiotics in otherwise healthy but immunocompro-
mised humans, but there is certainly a need for long term studies 
concerning the effectiveness and safety of probiotic supplementa-
tion within these populations. Unfortunately, the classical safety 
measurements such as the determination of toxicity or pathoge-
nicity of probiotic bacteria will always be hampered by the fact 
that simplified animal models or cell assays will inadequately 
mimic the complex gene-environment interaction in genetically 
susceptible human populations that might be at risk for the devel-
opment of chronic degenerative diseases (autoimmune, atopic, 
neurodegenerative or metabolic disorders) or complex acute dis-
eases (pancreatitis, sepsis).
Inadequate mechanistic understanding of probiotic activ-
ity. The lack of mechanistic understanding of probiotic activ-
ity is a major drawback for the prediction of safety of probiotic 
intervention. The complex gut-associated microbial ecosystem 
and nutrition-related factors are the most important environ-
mental triggers for the development and modification of chronic 
degenerative diseases including immune and metabolic patholo-
gies. In fact, the interaction between the gut microbial ecosys-
tem and the host is considered to be a critical factor in overall 
health or disease. Whether probiotics will exert protective or 
harmful, immune-stimulating or immune-suppressing effects 
on a host is dependent on the interplay between the microbial 
signals, the genetic make-up of the host and environmental trig-
gers. Many studies have revealed that certain probiotic bacteria 
stimulate immune cell proliferation and activity as evidenced by 
the production of cytokines and antibodies, thereby enhancing 
the effectiveness of the immune response against pathogens. In 
contrast, certain probiotics are able to reduce chronic inflamma-
tion and allergy, two diseases that are due to an overreaction of 
the immune system, by suppressing effector cells and inducing 
tolerance mechanisms, as was demonstrated for the treatment of 
inflammatory bowel diseases,23,24 or prevention of atopic derma-
titis.25 Experimental studies with VSL#3, a probiotic mixture of 
eight different bacterial strains, showed that this combination 
of strains directly suppress pro-inflammatory immune mecha-
nisms in an animal model of chronic colitis, in which VSL#3 
induced TGFβ-bearing regulatory T cells that confer protection 
to recipient mice after adoptive transfer. These studies suggest 
properties that may be related to health risks.14 For instance, the 
risk of Lactobacillus infection is estimated at about one case per 
10 million people over a century of probiotic consumption in 
France.5 Moreover, the risk of lactobacillemia was considered 
as ‘unequivocally negligible’, at <1 case per million individu-
als.15 Further evidence for safety was derived from a retrospec-
tive study that showed that increased probiotic consumption of 
Lactobacillus rhamnosus GG in Finland did not lead to increased 
cases of Lactobacillus bacteremia.16 Furthermore, clinical stud-
ies where certain probiotics have been safely administered to 
immunocompromised patients (for example, patients with HIV 
infection), premature infants, elderly and patients with Crohn’s 
disease without any side-effects provide further evidence of poor 
opportunistic pathogenicity.17,18
However, further investigation is warranted for probiotic use 
in at-risk human populations such as severely immunocompro-
mised subjects, neonates or hospitalized patients.18 For use in 
such sensitive populations, the use of appropriate in vitro assays 
or animal models for the assessment of infectivity should not be 
precluded. However, any toxicity or infectivity related to inges-
tion of candidate probiotics might only be evident when pushing 
the boundaries of current test systems, the results of which may 
be difficult to put into the context of the human situation.
The aim of this paper is to describe factors that need to be 
addressed when considering probiotic safety and to consolidate 
the opinions of the assembled experts on what topics require fur-
ther research.
Immunological Considerations for Safety
Immunological concerns have been raised regarding safety 
 assessments for probiotics from the perspective of the impact 
of probiotics on both the immunologically naive and immuno-
logically compromised host. Microbes—both indigenous and 
transient—impact the immune system. The indigenous intesti-
nal microbiota is known to be pivotal for the development and 
maintenance of gut physiology and immune homeostasis.19 The 
gut acts as a highly selective barrier and communication organ 
between the luminal bacterial environment and the host. The 
failure of this interaction due to the loss of barrier function or 
breakdown of tolerance mechanisms is thought to contribute to 
the development of inflammation-driven metabolic pathologies.
Risks of probiotic supplementation in healthy but 
 immunocompromised humans. The reported immune stimulat-
ing effects of probiotics could be especially beneficial in healthy 
people with somewhat compromised immune function, such 
as stressed or aged people, newborns as well as women during 
pregnancy. These groups are at increased risk of infectious and 
non-infectious diseases. It was already shown that probiotic sup-
plementation in aged people (>69) resulted not only in an increase 
of potentially beneficial intestinal bacteria such as bifidobacteria 
but also in an elevated activation of the non-specific immune 
response.20 It is unclear whether the observed immune cell activa-
tion after probiotic supplementation is sustainable or whether the 
effects of these short term interventions diminish with time. An 
indication that effects diminish with time was obtained by a study 
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have been conducted, which showed various results, ranging 
from no significant effects up to 93% reduction in post-operative 
infection rates. Importantly, no adverse effects of probiotics were 
demonstrated among these surgical patients. Surgical patients 
with high risk of bacterial infection, for instance after liver trans-
plantation or pancreatic surgery, benefited most from probiotic 
administration.
Even though the precise extent of the critical illness resulting 
from the operative procedure cannot be predicted, the timing of 
the induction of the illness is known, giving room for a possibil-
ity to start treatment even before the critical illness occurs. Seven 
studies have been published that enrolled these high risk patients 
(Table 1). All three studies that used probiotic treatment pre-
operatively were able to significantly reduce post-operative bacte-
rial infections, whereas only two of four trials showed any benefit 
of post operative treatment. Moreover, Sugawara and colleagues38 
demonstrated that consecutive pre-operative and post-operative 
probiotic treatment is more effective in reducing post-operative 
infectious complications than post-operative treatment alone.
However, the question of safety of probiotics for critically 
ill patients is paramount, especially in light of observations of 
higher mortality in a probiotic intervention group than a con-
trol group in a study using critically ill patients with acute pan-
creatitis.6 In this study, 296 predicted severe acute pancreatitis 
patients were allocated to receive either a probiotic mixture com-
prising six strains (four Lactobacillus and two Bifidobacterium) 
at 1010 CFU/day or placebo, starting within 72 hours of onset 
of symptoms for 28 days. The incidence of infectious compli-
cations was comparable between the groups (probiotics vs. pla-
cebo, 30% vs. 28%, respectively). However mortality rates were 
significantly higher in the probiotic group (16% vs. 6%) as was 
the incidence of bowel ischemia, which occurred in nine pro-
biotic-treated patients compared to none in the placebo group. 
Urine analysis demonstrated that in patients whose course of the 
disease was complicated by multi-organ failure, probiotic treat-
ment resulted in increased levels of intestinal fatty acid binding 
protein (IFABP), an accurate marker of intestinal mucosal injury 
resulting from ischemia.39 Furthermore, treatment with probiot-
ics resulted in an overall reduction in bacterial translocation (as 
gauged by decreased nitric oxide excretion into the urine) com-
pared to placebo-treated patients.40 However sub-group analysis 
showed that in patients with organ failure bacterial transloca-
tion was increased after probiotic treatment, indicating that pro-
biotics had beneficial effects in the moderately ill patients, but 
 deleterious effects in the critically ill.
The most obvious concern with probiotic use in patients with 
severe barrier dysfunction such as critically ill patients is the risk 
of sepsis due to the ingested probiotic agent. However in the 
trial conducted by the Dutch Acute Pancreatitis Study Group6 
no translocation of probiotic bacteria from the lumen into the 
systemic circulation was found. Therefore bacterial transloca-
tion of the probiotic bacteria to the systemic circulation did not 
 contribute to the adverse effects of probiotics in these patients.
Probiotics and endogenous defense systems. One of the 
 difficulties in assessing the place of probiotics in clinical prac-
tice is the limited understanding of their mechanisms of action, 
that certain strains of probiotics may trigger a protective memory 
in the adaptive immune compartment26 that goes beyond their 
interaction with the epithelial surface. The characterization of 
specific probiotic structure-function relationships in target popu-
lations will limit the risk of inducing converse detrimental effects 
in the host. Whereas probiotics are in general reported to protect 
the intestinal barrier, there might be conditions where probiotics 
not only fail to restore the intestinal barrier but facilitate translo-
cation or induce infections themselves. This is underlined by rare 
cases reporting the development of sepsis related to probiotic use 
in diseased patients.13 The reports about negative probiotic effects 
clearly show that it is necessary to unravel probiotic mechanisms 
in the context of the intestinal barrier function and host immune 
function, keeping in mind that effects are most likely specific for 
each probiotic strain or mixture used.
Use of Probiotics in the Critically Ill
Patients with great potential to benefit from probiotic  treatment 
are critically ill patients or patients who have a reasonable chance 
of getting into a critically ill state, such as patients who are 
about to undergo major abdominal surgery. During periods of 
critical illness, the gut can be hypothesized to be the motor of 
a pathophysiological state, as gut-barrier dysfunction can initi-
ate and propagate sepsis, systemic inflammatory response syn-
drome and multi organ failure.27 During critical illness, the 
equilibrium of the normally symbiotic partnership between the 
intestinal microbiota, epithelium and immune system is dis-
rupted. In critically ill patients, several factors are involved in 
the altered composition of the intestinal microbiota including the 
use of broad-spectrum antibiotics; changes in nutrient availabil-
ity, gut motility, pH and osmolarity; and release of high levels 
of stress hormones including catecholamines.28 Mucosal barrier 
dysfunction provides the opportunity for luminal opportunistic 
pathogens to translocate through the mucosal barrier, causing a 
marked pro-inflammatory response, which will increase the risk 
of systemic inflammatory response syndrome.
Probiotic strains and mixtures are potentially able to bolster 
this three-way equilibrium. Direct effects include fortification 
of colonization resistance by secretion of antimicrobial bacte-
riocins, competitive growth29 and reduction of pathogen adhe-
sion and invasion of epithelial cells.30,31 Furthermore certain 
probiotics are known to possess anti-apoptotic properties,32,33 
and to maintain cytoskeletal integrity and prevent disruption of 
tight junctions.34,35 But one of the most studied and well known 
mechanisms of action of probiotics is their immunomodulating 
capacity. For instance, probiotics have been shown to induce the 
release of anti-inflammatory cytokines such as interleukin-10,26 
to modulate human dendritic cell function,36 and to ameliorate a 
pro-inflammatory response.37
Probiotics in hospitalized patients. Critically ill hospitalized 
patients can be divided in two main categories: patients such 
as multi trauma or severe acute pancreatitis patients who are in 
an already critically ill state on admission and patients who will 
undergo major surgery. Considering the subgroup of patients 
undergoing abdominal surgery, ten randomized controlled trials 
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In contrast, probiotics administered before an expected  oxidative 
assault might result in an enhanced antioxidative capacity. This 
hypothesis is supported by the findings of Sugawara and col-
leagues,38 who showed that only peri-operative administration of 
probiotics was able to reduce bacterial infections after hepate-
ctomy while post-operative treatment alone did not seem to be 
effective. Of note, intravenous antioxidant therapy administered 
in the early phase of acute pancreatitis showed adverse effects in a 
recent randomized controlled trial,44 emphasizing the difficulties 
of targeting oxidative stress in acute pancreatitis.
Besides oxidative stress, an exaggerated pro-inflammatory 
immune response may also play a role in the development of 
multi organ failure during critical illness.27 In vitro studies show 
that certain probiotics can activate an anti-inflammatory defense 
system. For example, Voltan and colleagues45 showed that 
Lactobacillus crispatus downregulated expression of pro-inflam-




-induced  peroxisome 
proliferator.46
In conclusion, the characteristics of the cases of serious adverse 
events of probiotic treatment reported to date have identified 
the following risk factors: (1) immune compromised state; (2) 
impaired intestinal barrier function such as occurs with multi 
organ failure and severe acute pancreatitis; and (3) central venous 
catheter. As these factors are involved in critical illness, probi-
otic treatment is contraindicated for critically ill patients. The 
Norwegian Scientific Committee for Food Safety evaluated the 
safety of use of probiotics for hospitalized patients and simi-
larly concluded that probiotics should not be used for critically 
ill patients, including those with antibiotic-associated diarrhea 
(AAD), including Clostridium difficile infection.47 Probiotics 
seem to have a safer application as preventive treatment mea-
sures, applied well in advance of the surgical procedure. Even in 
especially their effects in patients suffering from or at risk of 
critical  illness. However, the available literature suggests that 
probiotics may have a safer place in preventive applications in 
hospitalized patients with peri-operative nutritional support than 
in treatment. In order to achieve success with such an approach, 
better understanding of probiotic-host interactions both in 
healthy and critically ill subjects is needed.
During a critical illness such as severe acute pancreatitis, 
mucosal barrier dysfunction is thought to be the sequelae of 
exaggerated and pathological immune responses and is often 
aggravated by low intestinal perfusion rates and intestinal oxi-
dative stress. Recent experimental work demonstrated that five 
days of probiotic pre-treatment before induction of acute pan-
creatitis stimulated glutathione biosynthesis in the ileum, result-
ing in attenuated acute pancreatitis-induced oxidative mucosal 
damage and intestinal barrier dysfunction.41,42 In addition, after 
five days of probiotic supplementation, increased gene expression 
of antioxidative defense enzymes was demonstrated. Increased 
expression levels of antioxidative enzymes could be indicative 
of cellular stress. Administration of probiotics may have caused 
a minor oxidative assault, such as intracellular accumulation of 
short-chain fatty acids produced by the bacteria, thereby induc-
ing increased capacity of antioxidant enzymes, preconditioning 
the mucosa for a major oxidative attack during acute pancrea-
titis. At first glance, this hypothesis may seem contradictory to 
the results of the recent placebo-controlled trial by Besselink and 
colleagues6 demonstrating increased incidence of bowel ischemia 
after administration of probiotics in the acute phase of severe 
acute pancreatitis. However, probiotics administered after the 
onset of acute pancreatitis may have acted as an extra oxidative 
burden in an already critically affected redox system,43 thereby, 
causing increased oxidative stress-induced damage and ischemia. 










surgery (liver gastric, 
pancreas colon)
5 post
109 L. plantarum 299 + oat 
fiber
30
109 heat killed L. 
 plantarum 299 + oat fiber
30 10% vs. 10% (n.s.)
134 Liver transplantation 12 post
109 L. plantarum 299 + oat 
fiber
31
109 heat killed L. 
 plantarum 299 + oat fiber
32 13% vs. 34% (n.s.)
204 Liver transplantation 14 post
Synbiotic 2000 (1010 of 4 
different LAB and 4 fibers) 
33 Fibers only 33
3% vs. 48%  
(p = <0.0001)
205 Hepatectomy 14 post
108 B. breve, 108 L. casei + 
enteral feeding
21 Enteral feeding 23
19% vs. 52%  
(p = 0.03)
Peri-operative treatment
206 PPPD 1 pre 8 post
Synbiotic 2000 (1010 of 4 
different LAB and 4 fibers) 
40 Fibers only 40
12.5% vs. 40%  
(p = 0.01)
207 PPPD 3–15 pre 10 post
E. faecalis, C. butyricum, 
Bacillus mesentericus 
30 No treatment 34
23% vs. 53%  
(p = 0.02)
38 Hepatectomy 14 pre 14 post
1010 B. breve, 1010 L. casei 
(perioperatively)
41
1010 B. breve, 1010 L. casei 
(post operatively only)
40
12.1% vs. 30%  
(p = 0.049)
PPPD, pylorus-preserving pancreaticoduodenectomy; post, post-operatively; pre, pre-operatively; L, Lactobacillus; B, Bifidobacterium; E, Enterococ-
cus; C, Clostridium. p values were calculated using Fisher’s exact test.
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and individual variability, resembled adult-type patterns. By 
7–10 days of age, most healthy full-term breast-feeding neonates 
are colonized with a heterogeneous bacterial microbiota includ-
ing Lactobacillus, Escherichia coli and Enterococcus, but with a 
clear cut predominance of Bifidobacterium. Among premature 
infants, Gewolb and colleagues61 showed that Bifidobacterium 
and Lactobacillus could be found in feces of only 5% of infants 
at one month of age, but these results remain to be confirmed 
with DNA-based detection techniques. The process of new-
born colonization is driven by exposure to the maternal vaginal 
tract, skin, rectum and the surrounding environment (hospital 
maternity wards, neonatal units, home deliveries). Other factors 
include mode of parturition and whether the infant is breast-fed 
or bottle-fed.62
Changes in the gastrointestinal tract environment have been 
shown to correlate actions in specific signaling pathways in the 
colonic epithelium, which has been proposed as a mechanism by 
which organisms associated with the mature intestine come to 
dominate the adult intestinal microbiota.63 It has been suggested 
that signals from the newly developing microbiota are causally 
related and trigger differentiation in the gut of newly hatched 
zebrafish.64 There is significant literature on the role of the micro-
biota on the development of the gut-associated immune system 
leading to clinical studies of probiotic organisms as treatment for a 
variety of diseases in neonates as well as its use in infant formula.
Risk of infections. The addition of probiotic bacteria to the 
diet of healthy, term babies must consider the risk that ingestion 
of live microbes could lead to infection. Typically, the probiot-
ics suggested for use in infants are species of Lactobacillus or 
Bifidobacterium, although Propionibacterium65 and S. thermo-
philus66 are also used. Lactobacillus are found in approximately 
0.1–0.2% of positive blood cultures from patients of all ages but 
sepsis or deep tissue infections resulting from ingestion of pro-
biotics are rare.67 However, case reports exist in the literature of 
serious systemic infections with ingestion of probiotic bacteria. 
Most of the reported infections from bacterial probiotics used 
in infants are related to L. rhamnosus strains. Two representa-
tive examples include L. rhamnosus GG sepsis in a complicated 
post-operative period following repair of a double-outlet right 
ventricle and pulmonary stenosis and a report of two infants with 
short gut syndrome.3,12 For these cases the clinical blood isolate 
and supplemental probiotic underwent DNA fingerprinting by 
repetitive element sequence-based polymerase chain reaction 
or pulsed field electrophoresis (PFGE) of chromosomal DNA 
digests confirming identical band patterns.
There are also case reports of serious infections by organ-
isms generally presumed to be non-pathogenic in infants. 
For instance, case reports have been published documenting 
Bifidobacterium breve meningitis and Pediococcus sepsis in infants 
with gastroschisis.68,69 Although these cases were not associated 
with probiotic usage, they do highlight the concept that even 
presumed non-pathogenic organisms might cause infection in 
at-risk populations.
One of the issues involving the widespread administration 
of probiotics to infants is the difficulty in defining infants that 
are in a greater at-risk category. Of note is a study undertaken 
light of the outcome of the PROPATRIA study,6 probiotics hold 
promise to prevent complications in patients at risk of becom-
ing critically ill, such as patients scheduled for major abdominal 
surgery. The safety concerns are paramount in this compromised 
patient group and use in this application is clearly the purview of 
a p robiotic drug, not food.
Use of Probiotics in Patients  
with Inflammatory Bowel Disease
Inflammatory bowel diseases (IBD) are chronic  inflammatory 
conditions of the intestinal tract that affect children and adults 
and cause significant morbidity and occasional mortality. 
Inflammatory diseases of the bowel include Crohn disease (CD) 
and ulcerative colitis (UC). Probiotics have been investigated 
for effectiveness in reducing active disease or extending remis-
sion in both CD and UC. Additionally, they have been tested as 
agents to extend disease-free periods in patients suffering from 
pouchitis, an inflammation of a pouch created surgically after 
colon removal. No benefit of various probiotic preparations was 
observed with studies on induction of remission, prevention of 
recurrence of CD following active disease, or for prevention of 
post-operative recurrence.48-50 Evidence for extending remission 
for patients with pouchitis was found,51,52 but a study by another 
research group did not find the same product to be effective.53 
A systematic review did not find any benefit to combining pro-
biotics with standard therapy for remission of CD in mild to 
moderate disease.54 There was some evidence for a slight decrease 
in severity of active UC observed in four studies using a single 
Bifidobacterium strain, an Escherichia coli strain and two multi-
strain probiotic products.54 Since that time there have been 
additional studies that reported some benefit (including small 
pediatric trials one of which was of open label design); all subjects 
enrolled in these trials had mild to moderate disease.55-58
Use of probiotics in cases of active disease, where mucosal 
ulceration and exposure of the submucosa is present, could carry 
an increased risk of bacterial translocation and secondary bac-
teremia. Indeed, sepsis with a Lactobacillus rhamnosus strain 
was reported in a patient with severe colitis.59 Thus, caution in 
severely ill patients much the same as in other very ill patients is 
warranted before consideration of administration of probiotics in 
active UC.
Use of Probiotics in Healthy, Term Infants
Newborns enter this world with a sterile gut. However, they are 
immediately exposed to a contaminated environment and natural 
bacterial colonization begins early on the first day of life. Palmer 
and colleagues60 tracked the process of bacterial colonization 
of the full-term newborn by analyzing stools using a microar-
ray developed to detect and quantify the RNA gene sequences of 
most currently recognized taxonomic groups of bacteria. They 
found that bacterial colonization was specific to each infant and 
was unstable over the first few weeks of life. This initial period 
of flux and instability was resolved by one year of life when the 
bacterial communities, although marked by a degree of temporal 
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stopped at the time of delivery, all four vaginally delivered infants 
had the probiotic detectable in the stool for six months, three for 
one year and in one infant until two years of age.85 In a larger 
study with a primary outcome of prevention of atopic dermatitis 
at two years of age, L. rhamnosus GG or placebo was adminis-
tered to mothers for 4 weeks before delivery, and either directly to 
the infant (N = 38) or to the breast-feeding mother (N = 25) for 
6 months.77 Stools collected 6 months later showed between 20% 
and 26% (depending on method to detect L. rhamnosus GG) 
remained positive for this organism.86 Although the study was 
complicated by a high incidence of the organisms in the controls 
in a country with high ingestion of this probiotic, these studies 
suggest a predisposition for some infants to be more protracted 
carriers of this probiotic strain than others. In addition, an increas-
ing incidence of diseases involving the immune system over the 
last several decades has been thought to be a consequence of too 
few antigenic challenges to the developing immune system due 
to the increased sterility of the environment.87 However, admin-
istration of one or a few single probiotic strains in high numbers 
does not represent a natural approach to colonization and raises 
the possibility of long-term adverse unintended consequences 
such as increased allergic manifestations reported in three studies 
following administration of Lactobacillus to infants:
• Kalliomaki and colleagues77 followed a cohort of individu-
als whose mothers and/or the infants received L. rhamnosus GG 
for a six-month period following birth to evaluate the preven-
tion of atopic dermatitis. The seven year follow-up88 reported that 
whereas the cumulative risk for developing eczema was lower in 
the infants administered probiotic, the risk for allergic rhini-
tis and the more serious asthma was increased in the probiotic 
group.
• Kopp and colleagues89 conducted a study with similar design 
with one significant difference; breastfeeding mothers, not 
infants, directly received L. rhamnosus GG until the infants were 
3 months of age, at which time all infants were fed the probiotic 
or placebo. Only five non-breast fed infants directly received the 
intervention before the age of 3 months. In this study, increased 
wheezing bronchitis was observed in participants that received 
L. rhamnosus GG compared to the control group.
• Taylor and colleagues90 conducted a study of similar design 
but with a different probiotic. Lactobacillus acidophilus LAVRI-A1 
was administered directly to newborns for the first 6 months of 
life. There was no effect on prevention of atopic dermatitis but 
an increased rate of sensitization was observed in the probiotic 
group. However, a follow-up after the third year of life found that 
“[the tested strain] did not have any long-term effects on allergic 
outcomes. Specifically, the higher rates of sensitization that were 
previously seen at 1 year of age in the probiotic group were no 
longer apparent in the third year of life”.91
Conclusions on safety of probiotics for full-term infants. The 
use of infant formulas containing Lactobacillus, Bifidobacterium 
and/or S. thermophilus is currently allowable in parts of Asia, 
Europe and in the United States. Numerous studies have 
been conducted on full-term and premature infants, with no 
 short-term, serious adverse events being reported. However, 
 long-term effects have only rarely been measured and some 
to evaluate the efficacy of probiotic administration in reducing 
nosocomial infection in the pediatric intensive care unit setting. 
Rising concern about the use of L. rhamnosus GG and an interim 
analysis revealing a trend (but statistically non-significant) toward 
increased nosocomial infections in those subjects receiving 
L. rhamnosus GG compared to placebo led to premature closure of 
the study.70 Thus, there remains a significant need to better define 
at-risk infant groups to include level of prematurity, degree of 
underweight for very low birth weight infants, the minimum safe 
level for total white blood counts and neutrophils, the structural 
defects that place infants at risk (such as defects in heart or gut), 
immune and non-immune protective defects and whether altera-
tions to the intestinal barrier function are a significant threat. 
Inflammation of the intestinal mucosa as observed in infants with 
short bowel syndrome may be an additional risk factor.
Growth. For infant formula studies, growth is a primary 
determinant of safety. In their study with growth as a primary 
outcome, Saavedra and colleagues66 studied a formula contain-
ing Bifidobacterium animalis subsp. lactis Bb-12 and Streptococcus 
thermophilus TH-4 in 131 healthy infants aged 6 months and 
older. They found no difference in growth between infants tak-
ing a formula with the two different probiotic bacteria and those 
infants on an identical formula that did not contain the probiotic 
microbes. Another study involved 201 healthy 4- to 10-month-
old infants recruited from multiple day-care centers. They were 
fed formula with either B. animalis subsp. lactis Bb-12 or L. reu-
teri SD 2112 and investigators did not detect any differences 
when examining growth compared to an identical formula with-
out added probiotics.71 In another study with primary outcome 
being growth for infants receiving at least 50% of their feeds 
from formula, 120 infants between birth and 2 months of age 
were randomized either to receive their formula unchanged or 
with L. rhamnosus GG.72 The authors of this study reported that 
the study group receiving the probiotic group grew better but this 
result is controversial.73 Other research in which no differences in 
growth were detected between infants receiving probiotic-sup-
plemented formula and controls include studies with L. reuteri 
ATCC 55730;74 with L. rhamnosus LPR, Bifidobacterium longum 
BL888, and Lactobacillus paracasei ST11;75 with B. animalis 
subsp. lactis CNCM I-3446;76 with L. rhamnosus GG;77 with L. 
rhamnosus GG and LC705, B. breve Bb99, and Propionibacterium 
freudenreichii subsp. shermanii;78 with B. longum BL999;79 with L. 
paracasei subsp. paracasei CRL-431 and B. animalis subsp. lactis 
Bb-12;80 and with L. rhamnosus HN001 or B. animalis subsp. lac-
tis HN019.81,82 Thus, there is no evidence of compromised growth 
for infants receiving probiotic containing formula with strains 
studied. Noteworthy is a decades-old study83 in which newborn 
infants in their first three months receiving a formula containing 
0.35 to 0.5 grams of lactic acid to 100 grams of milk formula for 
10-day periods had significant problems with growth.
Long-term colonization and immunologic effects. Generally 
speaking, probiotics have not been found to establish intestinal 
colonization for long periods of time.84 However, exposure of 
younger infants may lead to long-term colonization. For instance, 
in a study evaluating the colonization of infants whose  mothers’ 
ingested L. rhamnosus strain GG during late pregnancy, but 
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probiotic strains (one L. acidophilus and one Bifidobacterium 
bifidum) in either breast milk or breast milk and formula twice 
daily for six weeks. No episodes of sepsis from either Lactobacillus 
or Bifidobacterium were evidenced during this study.94 This his-
tory of safe consumption of some probiotics has generally been 
considered proof of short term safety for this vulnerable popula-
tion of infants but, as always, proof of safety of a specific strain 
requires study of that strain rather than extrapolation from 
related strains.
In summary, preterm infants represent a unique situation. 
The aberrant fecal colonization resulting from prematurity pro-
vides an important rationale for the use of probiotics in these 
high risk neonates, which is different from any other population. 
In this population, probiotics offer an opportunity to expose the 
at-risk neonatal intestine to microbes not associated with pathol-
ogies thereby reducing the threat from exposure to less innocuous 
colonizers and subsequent development of NEC.
Long term effects. Nevertheless, precisely because we are 
intervening at a stage of developmental immaturity, the potential 
for a given treatment to result in a long term impact is magni-
fied. However, no cohorts from probiotic intervention studies 
conducted with premature infants have been followed long-term 
with regard to the impact of probiotics on colonizing microbiota, 
leaving a gap in the direct observation of any long-term effects.
Our understanding of the interaction between the intesti-
nal microecology and the development of the intestinal innate 
immune system is only beginning to evolve. Likewise, our knowl-
edge of the interaction of neonatal exposures and the develop-
ment of subsequent atopic phenomena is insufficient. Hypotheses 
have been advanced suggesting that changes in the microbial 
environment of the gastrointestinal tract brought about by probi-
otics given during infancy may play a role in diseases that mani-
fest later in childhood such as allergies, atopy, and perhaps even 
autoimmune disorders such as type 1 diabetes. The increasing 
prevalence of these diseases in certain geographic locations has 
fueled interest in this area as a focus of research.
Studies of gnotobiotic animals show that a normal microbi-
ota is needed for intestinal angiogenesis,98 for the development 
of normal immune function99 and normal intestinal epithelial 
development,100 and for normal gut motility and peristalsis.101 
Conversely, introduction of normal microbes or even of only one 
species of a commensal bacterium to gnotobiotic animals restores 
intestinal function, mucosal proliferation and immune develop-
ment, and improves barrier function.102 This potential to impact 
intestinal development would be expected to have both short and 
long-term implications.
In summary, in the case of Lactobacillus and Bifidobacterium 
probiotic administration to premature infants at-risk for develop-
ing NEC must be considered from the perspective of risk and ben-
efit. Since the typical condition of the premature neonate is one of 
developmental intestinal deprivation, and since no adverse effects 
have been reported to date on probiotic intervention trials with this 
susceptible group, and since prevention of NEC has been achieved 
through probiotic intervention, the debate may be shifted from 
whether or not it is safe to give probiotics to the premature neonate 
to whether it is safe not to give probiotics to premature neonates. 
question remains about the ability to identify at-risk infants at 
the time of birth. Furthermore, newborn infants are microbio-
logically and immunologically naïve, and as such are a vulnerable 
population. Immune effects, as well as other endpoints, can be 
expected to be strain-specific, so safety studies should be done for 
specific strains in infants and not extrapolated from data on taxo-
nomically related strains. Metabolic activity such as the ability to 
produce D-lactic acid must be evaluated and disclosed to preclude 
use by infants with known underlying defects or conditions. The 
presence of any antigenic material (such as milk proteins) that 
may be contained in the probiotic product should be disclosed 
on labelling. The use of probiotics for the treatment or preven-
tion of disease should be under the supervision of physicians. 
Further studies are warranted on the long-term consequences of 
manipulation of the intestinal microbiota by administration of 
single or limited number of bacteria in high-concentration probi-
otic supplements for prolonged periods of time. Any widespread 
administration of such infant foods requires careful and compre-
hensive post-marketing surveillance to monitor for unintended 
consequences.
Use of Probiotics in Premature Infants
Short term effects. The intestinal bacterial colonization of  preterm 
neonates differs both temporally and qualitatively from full term 
infants. Because neonatal intensive care is characterized by pro-
longed separation from the mother, delayed enteral feeding, a 
relatively sterile environment (incubators) and frequent use of 
broad-spectrum antibiotics, the natural colonization process tends 
to be both delayed and impaired. Preterm neonates are colonized 
by fewer bacterial strains, their microbiota is more likely to be pop-
ulated by pathogenic bacteria, and bifidobacteria are undetectable 
in the intestinal microbiota during the first 1–2 weeks after birth 
and do not predominate until after the third week of life.92
The immature intestine is further characterized by impaired 
mucosal barrier function leading to increased gut permeability. 
Normally, at this stage of immature development, the intes-
tine is protected by a sterile fetal environment. However, when 
thrust prematurely into the hostile outside world, and exposed to 
potentially pathologic bacteria before its barrier function is fully 
developed, the leaky intestine becomes extremely susceptible to 
microbial invasion, which may culminate in necrotizing entero-
colitis (NEC), a disease with a mortality of 20–50% and signifi-
cant long term morbidity in survivors.
Several studies,93-96 provide compelling evidence that prophy-
lactic administration of certain Lactobacillus, Bifidobacterium 
and S. thermophilus probiotics in this population reduces both 
the incidence and severity of NEC, thereby conferring short term 
health benefits to premature neonates. To date over 2,000 prema-
ture neonates have been exposed to prophylactic probiotics in dif-
ferent prospective studies and no adverse short term effects have 
been noted. For example, Dani and colleagues97 administered 
109 CFU/day L. rhamnosus GG to 295 very low birth weight 
infants and there were no Lactobacillus infections. Similarly, in 
a  multicenter, randomized controlled study involving 434 very 
low birth weight infants, the study group was administered two 
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require specialized equipment, up-to-date databases with reliable 
reference material and trained personnel that may not be readily 
available in all companies producing probiotic products. In addi-
tion, DNA fingerprints are less exchangeable and reproducible 
among laboratories compared to sequencing data. Depending on 
the method and group of organisms in question, this may ham-
per the verification of identification results between independent 
expert laboratories.
Due to the growing availability of whole bacterial genome 
sequences, sequence-based identification approaches have in 
recent years been intensively explored for bacterial taxa com-
monly used as probiotics. In the hands of probiotic producers, the 
use of partial or complete sequencing of the 16S rRNA gene has 
become a standard method for species identification of their cul-
tures. However, there are potential drawbacks to this approach, 
such as the presence of unreliable or poorly documented sequence 
entries in public sequence databases (EMBL/GenBank/DDBJ) 
or the low taxonomic resolution to separate closely related (sub)
species such as those belonging to the Lactobacillus plantarum 
group and the Lactobacillus paracasei group or within the spe-
cies Bifidobacterium animalis and Bifidobacterium longum.105 
Compared to 16S rRNA, the use of single-copy protein-coding 
(housekeeping) genes pheS and rpoA for lactobacilli115 and atpD, 
tuf, groEL and recA for bifidobacteria116 generally offers a higher 
discriminatory potential. The application of these molecular 
markers has a large potential in the probiotic field because they 
are easily accessible through outsourcing services, although data 
interpretation by taxonomic experts remains crucial to ensure reli-
ability of the identification result. Another approach common in 
the bacterial systematics literature is the combination of informa-
tion from 16S and one or two additional genes, a technique that 
was recently shown to help discriminate among related strains 
from B. subtilis and closely related species.117 Due to advances 
in DNA sequencing technology significantly increasing capacity 
and speed at reduced cost, it is expected that more and more pro-
biotic candidate strains will be identified through whole-genome 
sequencing. Yet, an important challenge lies downstream of this 
approach at the level of data analysis, data interpretation and 
interchangeability of techniques and conclusions.
Colonization. The relevance of long-term or permanent 
colonization as a safety criterion for probiotics should not be 
generalized across all hosts, all probiotic strains or all possible 
colonization sites. As previously discussed in this paper, the 
administration of probiotics to mothers of healthy infants can 
lead to long-term colonization of six months and longer,85,86 but 
few data are available on colonization and persistence when the 
probiotic is directly administered to full-term or preterm infants. 
Furthermore, even though most studies focus on colonization of 
intestinal mucosa or feces, there are many potential niches along 
the gastrointestinal tract, from the mouth to the rectum, and 
the vaginal tract, which should be considered. This is especially 
important with increased focus on development of probiotics 
specifically for activity in the mouth, throat, stomach, skin and 
vaginal tract.
The reported evidence for long-term colonization in the 
 gastrointestinal tract of adults is sparse. Although the design of 
The premature neonatal population is unique vis a vis administra-
tion of probiotics because normal gut microbial colonization has 
not yet developed, potentially contributing to severe pathology. 
Some tested strains of Lactobacillus and Bifidobacterium probiot-
ics appear to have short term health benefits in this population 
and no major short term adverse effects. It is also true, however, 
that the potential for long term  probiotic-related adverse effects 
has not yet been completely defined.
Microbiological and Metabolic Issues Related 
to Safety
Identification. Although sometimes overlooked as a safety 
 criterion, correct assessment of taxonomic identity should be 
scheduled as early as possible in the screening process for new pro-
biotic candidate strains.103-105 Correct identification of probiotic 
strains to the species level is essential for safety assessment as it 
allows a linkage to potentially relevant, species-related scientific 
and technological information, including data on growth con-
ditions, metabolic characteristics and genomic information. In 
addition, strains must be identified to the strain level.103 The abil-
ity to identify a specific probiotic strain among other probiotics or 
members of the native microbiota is essential for strain selection 
and characterization, assessments of strain stability throughout 
the manufacturing process, for proper description of material used 
in human intervention studies, efficient tracking of the probiotic 
through the host, and for post-market surveillance including 
matching of strains isolated from any suspected infections.
The majority of probiotic microorganisms for human use 
belong to the taxonomically complex LAB and bifidobacte-
ria. For the identification of probiotic LAB or Bifidobacterium 
strains, the use of phenotypic tests or commercial identifica-
tion systems such as API,105,106 are inadequate for species level 
resolution. Furthermore, typing methods (such as pulsed-field 
gel electrophoresis and randomly amplified polymorphic DNA 
analysis) are primarily useful for differentiation of individual 
strains, but are otherwise unsuitable for species recognition. At 
present, the inappropriate use of identification methods is con-
sidered to be the major cause of mislabeling of probiotic prod-
ucts reported worldwide.107,108 Inconsistencies in the microbial 
identification for commercial products with probiotic claims 
affects their potential efficacy and safety record, and are likely 
to have a negative impact on consumer trust. There are examples 
of such misattribution of products labeled as Bacillus subtilis but 
actually containing other species.109,110
Triggered by the limitations of phenotypic approaches and the 
increasingly important role played by molecular tools in the field 
of bacterial systematics, a range of DNA methods either based 
on fingerprinting or on sequencing has been used for the iden-
tification of probiotic bifidobacteria and LAB.111 Fingerprinting 
methods that have been most commonly used for this purpose 
include amplified fragment length polymorphism,106,112 repetitive 
DNA element (rep)-PCR106,107 and ribotyping.113,114 The major 
advantage offered by several of these methods is that they yield 
information not only at the species level but in some cases even 
up to the strain level. However, fingerprinting methods usually 
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in Food Chain” (ACE-ART) projects, the Joint International 
Organization for Standardization-International Dairy Federation 
(ISO-IDF) Action Team on Probiotics and other research proj-
ects.105,122-126 One of the most crucial aspects in communications 
concerning antibiotic resistance in probiotic or nutritional cul-
tures is to separate intrinsic resistance from acquired resistance. 
In the latter category, it is furthemore important to distinguish 
resistance caused by random genetic changes on chromosomal 
genes (such as topoisomomerase inactivation leading to quinolone 
resistance or ribosomal changes leading to rifampicin resistance) 
from those more likely to be transmissible (such as vancomycin or 
tetracycline resistance elements that frequently reside on geneti-
cally mobile elements such as plasmids or transposons). While 
the mechanisms and frequently even specific genes are widely 
studied in pathogenic bacteria, there is almost no published lit-
erature that examines the mechanisms of antibiotic resistance in 
 bacterial genera that do not contain pathogens.
In the PROSAFE project, the MICs of 16 antimicrobials 
 representing all major classes were determined for 473 taxonomi-
cally well-characterized LAB isolates encompassing the genera 
Lactobacillus, Pediococcus and Lactococcus.123 It was found that 
breakpoints for phenotypic antibiotic resistance assessment must 
be obtained at species or species group level, and as a result, ten-
tative epidemiological cut-off values of 13 antibiotics were deter-
mined for up to 12 LAB species. Six probiotic and nutritional 
cultures of Lactobacillus that displayed phenotypic resistance 
to oxytetracycline and/or erythromycin possessed erm(B) and/
or tet(W), tet(M) or unidentified members of the tet(M) group. 
In vitro intra- and interspecies filter-mating experiments failed 
to show transfer of resistance determinants. Three probiotic 
Lactobacillus strains were highly resistant to streptomycin, but 
no corresponding resistance gene could be detected by PCR. As 
one of the important conclusions from the PROSAFE project, 
the finding of acquired resistance genes in isolates intended for 
probiotic or nutritional use highlights the importance of anti-
microbial susceptibility testing in documenting the safety of 
 commercial LAB.
In the ACE-ART project, a collection of 1,579 strains mainly 
from food origin was amassed from species of Lactobacillus (n 
= 843), Bifidobacterium (n = 467), Lactococcus (n = 178) and 
Streptococcus thermophilus (n = 91). Methodology was shown 
to be of paramount relevance (growth medium, inoculum size, 
incubation time) and methods for all four bacterial groups were 
developed, based on previous work by Klare and co-workers.122 
A limited number of antibiotics were tested including ampicil-
lin, tetracycline, erythromycin, clindamycin, gentamicin, strep-
tomycin and, only for Bifidobacterium, vancomycin. To reliably 
establish species-specific breakpoints, it was the aim to collect a 
sufficient number of genotypically unique strains (approximately 
50 was judged to be the target number) of each species to reflect 
possible variations in biological source and/or geographical ori-
gin. However, not all tested species were represented by a large 
number of strains. Findings from phenotypic susceptibility tests 
indicated that molecular characterization using PCR detection 
or microarrays must be done when the resistance phenotype for 
a particular strain falls outside the breakpoint defined for the to 
prolonged monitoring studies in healthy subjects or patient groups 
who take a specific probiotic on a regular basis seems relatively 
straightforward, there are several factors that may complicate the 
outcome. First, the long-term ability of a probiotic strain to colo-
nize the intestinal tract depends on its ability to survive through 
and grow in the gastrointestinal tract. For some probiotic strains 
such as Lactobacillus casei Shirota, it has been shown that a more 
permanent colonization may be hindered by the low rate of cell 
division.118 In the mouse intestine, the average doubling times 
of the Shirota strain estimated from the residual fluorescent lev-
els of surface-adhered cells were 4.10, 4.78, 4.56 and 5.59 days 
in the duodenum, jejunum, ileum and colon, respectively. Lee 
and colleagues118 estimated that the strain would need a much 
shorter average doubling time of 1.03 to 2.04 days to colonize the 
various sections of the mouse intestinal tract more permanently. 
Also, any assessment of intestinal colonization in the most rep-
resentative way would require jejunal or rectal mucosal biopsies 
rather than fecal samples. Alander and colleagues119 compared 
both sample types in their study on the persistence of L. rham-
nosus GG in human volunteers undergoing routine diagnostic 
colonoscopy. Based on the finding that seven out of the 21 sub-
jects scored positive in biopsies but negative in fecal samples for 
the presence of strain GG, the authors concluded that the study 
of fecal samples alone is not sufficient in evaluating colonization 
by a probiotic strain. In critically ill patients, however, the collec-
tion of rectal biopsies to monitor probiotic colonization may hold 
inherent risks and will rarely be approved by ethical committees 
for large patient populations.120 Consequently, the use of animal 
models may currently be the safest way to study long-term colo-
nization.105 Nevertheless, interpretation of probiotic safety data 
from animal models remains controversial. It has been shown 
that the route and dose of administration for Bacillus strains in 
mice may highly influence the outcome of toxicity tests,121 and it 
is to be expected that these and other pharmacological parame-
ters may also affect the outcome of long-term colonization  studies 
in animal models.
Antibiotic resistance and transferability. Antibiotic  resistance 
expression and transferability of antibiotic resistance determi-
nants from fed probiotic strains to commensal microbiota in vivo 
are important components of the safety assessment of bacteria 
used as probiotics. Assuming that the probiotic in question does 
not present a risk of infectivity, the primary concern with the 
presence of antibiotic resistance genes is that probiotic strains 
should not function as a potential source of antibiotic resistance 
genes to less innocuous microbial members of the intestinal 
microbial ecosystem. In vivo transfer to potentially more harm-
ful microbes (commensal or transient) is a theoretical concern 
which is extremely complex to assess in practice. Recently, the 
vancomycin resistance gene, vanA, was transferred in an animal 
model from an Enterococcus strain to L. acidophilus, providing 
evidence that transfer can take place in vivo.22
Currently, there is not a harmonized approach worldwide 
to this issue. This topic has been addressed by the European 
Union-funded “Biosafety Assessment of Probiotics used for 
Human Consumption” (PROSAFE) and “Assessment and 
Critical Evaluation of Antibiotic Resistance Transferability 
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• A likely mechanism for transfer of this gene was not found
• The likelihood of transfer of tet(W) from Bb-12 to other 
microorganisms is considered very low
• Tetracycline resistance is relatively common among lactic 
acid bacteria used in food
• The tet(W) gene is relatively common among human com-
mensal gut bacteria
• Strain Bb-12 is commonly used in a number of food prod-
ucts in the U.S. and other developed countries with no known 
adverse events attributed to its tetracycline resistance
• Consumption of Bb-12 would not compromise clinical use 
of tetracycline, since tetracycline is not recommended in children 
younger than 8-years-old.
Genetic stability/genetic transfer. The genetic stability of a 
probiotic strain reflects the susceptibility to genomic rearrange-
ments in the course of its natural evolution. These rearrangements 
may reflect small variations introduced at specific or random posi-
tions of the genome through mutations, deletions and insertions, 
but may also be linked to larger structural variations  resulting 
from homologous recombination (vertical inheritance) and hor-
izontal gene transfer events. Although this is a highly relevant 
issue in order to ensure that specific health-promoting character-
istics and functionalities are not affected during long-term pres-
ervation and production, surprisingly few studies have reported 
comprehensive data documenting the genetic stability of com-
monly used probiotic strains.
Ideally, a rigorous assessment of a strain’s genetic stability 
requires the availability of its whole-genome sequence. In the 
absence of this information, however, the use of molecular typing 
techniques probably provides the best estimate of genetic stability 
at the individual strain level. This estimate can be based on geno-
typic comparisons between re-isolates of a given probiotic strain, 
such as re-isolations before and after gastrointestinal passage 
or throughout the course of production. Within the European 
Union-PROSAFE project, the genotypic and phenotypic stabil-
ity of a probiotic candidate strain, L. rhamnosus PRSF-L477, was 
assessed in a randomized, placebo-controlled, double-blind, par-
allel-group study of 36 healthy volunteers.105 PFGE analysis was 
used to track strain PRSF-L477 in fecal samples of nine subjects. 
Based on the highly identical if not indistinguishable PFGE pro-
files exhibited by the original strain and its fecal re-isolates, the 
investigators concluded that PRSF-L477 did not undergo major 
genomic rearrangements thus indicating its genetic stability dur-
ing healthy gastrointestinal tract passage. Deposit of all commer-
cial probiotic strains into an internationally recognized culture 
collection will provide an enduring source of reference material 
for confirmation of genetic stability.
Alternatively, indirect evidence for genetic stability may also 
be obtained from genotypic screening of collections of probiotic 
cultures belonging to a single taxonomic group but collected from 
various geographical origins. Following this approach, a subset of 
118 L. rhamnosus isolates mostly from human fecal or clinical 
origin131 included 14 commercial strains that were received from 
10 different producers or distributors of probiotic products. The 
integrated use of AFLP and PFGE fingerprinting revealed that 
some of these probiotic strains were indistinguishable from one 
which it species it belongs. In most cases, erm and tet resistance 
determinants were found in strains displaying a high MIC value 
for the particular antibiotic, corresponding with a resistant phe-
notype.127 Of these, the most frequently identified genes included 
tet(W), tet(M), tet(S) and erm(B). However, the correspondence 
between phenotype and genotype was not always straightfor-
ward, since 22 isolates with a susceptible phenotype seemed to 
harbor tet or erm genes. Also in the opposite way, in at least 15 
phenotypically resistant strains no corresponding resistance gene 
could be identified by microarray analysis in which case resis-
tance may be due to mutations in intrinsic genes and is not linked 
to transferable resistance genes.
Although the PROSAFE and ACE-ART projects represent 
significant progress toward developing the needed construct for 
generating and interpreting information on antibiotic resistance 
among bacteria intended for human food use, some questions 
remain unanswered. Remaining research needs include:
• The range of antibiotics being tested must be expanded to 
include all those relevant to human clinical applications.
• Not enough strains are available for some species to reli-
ably establish the norm for inherent resistances for a species. 
Additional strains would make conclusions more robust.
• The risk of transfer of antibiotic resistance determinants from 
a fed probiotic strain to commensal microbiota in vivo has not 
been assessed experimentally. However, it should be emphasized 
that an antibiotic resistant strain of Lactobacillus, Bifidobacterium 
or S. thermophilus is not a pathogen.
• It has been suggested15 that probiotics for human use should 
be susceptible to at least two clinically relevant antibiotics. 
However, since clinical susceptibility is not always predicted by 
in vitro testing, the link between in vitro antibiotic susceptibility 
and in vivo susceptibility must be better understood.
An additional concern is the use of distributions of data points 
from collections of isolates to establish breakpoints for antibiotic 
resistance testing. This practice, while accepted by the European 
Food Safety Authority for animal feed applications128 differs from 
those used to establish breakpoints used by clinical laboratories in 
the United States. For clinical applications, antibiotic resistance 
breakpoint testing is less likely to be a wild-type cutoff value 
(derived from diverse diagnostic laboratory collections) and is 
more likely to be a clinical value (derived from a clinical field trial, 
or a pharmacokinetic/pharmacodynamic cutoff value) based on 
the relationship between achievable drug concentrations at the 
site of infection and the dynamics of the antimicrobial activity of 
the drug. Values used by clinical laboratories are generally those 
published by the Clinical and Laboratory Standards Institute.129
As a practical example, it is interesting to consider the FDA 
reaction to the presence of genes for tetracycline resistance in the 
commercial probiotic strain, B. animalis subsp. lactis Bb-12,130 
(in the opinion text, the taxonomically incorrect species name B. 
lactis was used). A partial tet(W) gene was found residing on the 
chromosome of Bb-12. However, the FDA did not question the 
conclusion of the manufacturer’s expert panel that this did not 
impact the assertion that this strain was GRAS for its intended 
use as an ingredient in infant formula. This conclusion of the 
panel was based on the following rationale:
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GG with another group ingesting heat-killed L. rhamnosus GG 
for the prevention of allergies in infants, Kirjavainen and col-
leagues135 reported increased gastrointestinal symptoms and 
diarrhea in those ingesting the formula with the heat-killed 
product, which led the Review Ethics Board to prematurely 
discontinue the study. In another study,136 micronutrients were 
combined with either a heat-inactivated L. acidophilus probiotic 
strain or placebo and the impact on the prevalence of diarrhea 
in an at-risk group of children was assessed. The benefits of the 
micronutrients were negated by the addition of heat-inactivated 
probiotics. The prevalence of diarrhea in children receiving the 
combination of micronutrients and heat-killed preparation was 
the same as placebo with both being worse than micronutri-
ents given alone.136 Thus, the importance of ingestion of viable 
probiotics is important not only from an efficacy point of view 
but possibly from an association of dead microbes with adverse 
effects. Products comprising heat-killed microbes should not 
be made available to infants until any adverse effects from such 
products are better understood.
Pathogenicity/toxicogenicity. Factors that could play a role in 
the virulence of a microorganism might include adhesion mecha-
nisms allowing adherence to mammalian cells, mucin degradation 
providing metabolites for growth, and bile salt hydrolase activity 
enhancing survival in the gut environment. However, these fac-
tors also contribute to the survival of microorganisms in the mam-
malian gut, and as such are characteristics of much of the natural 
microbiota. Therefore, they are not a priori meaningful measures 
of virulence. Furthermore, in vitro measurements of these factors 
are not necessarily good predictors of in vivo activity.
For bacterial groups for which no known pathogenic mem-
bers are known, it is difficult to assess what potential virulence 
factors might exist. No genes associated with pathogenicity have 
been identified in Lactobacillus or Bifidobacterium species used 
as probiotics. Although several reports of sepsis in at-risk indi-
viduals have been linked to lactobacilli, there is no conclusive 
evidence from analysis of clinical isolates that would indicate 
any species-related properties that would favor infection in at-
risk populations.14 Asahara and colleagues137 have suggested that 
resistance to host innate defence mechanisms should be consid-
ered in the safety assessment of Lactobacillus strains, but research 
in this area is limited.
On the contrary, numerous virulence factors in enterococci 
have been reported, including hemolysin, gelatinase or DNAse 
activities, or the presence of structural genes cylL, ace, asal and 
esp.138,139 However, there is no consensus on a method or proce-
dure for reliably differentiating pathogenic from non-pathogenic 
strains. Pathogenic species of streptococci produce hemolysins, and 
a surface enolase that binds and activates human plasminogen.140 
Strains of Bacillus species licheniformis, pumilus and subtilis have 
occasionally been reported as causative agents in food poisoning. 
For Qualified Presumption of Safety (QPS) status, EFSA requires 
demonstration of the absence of Bacillus toxins by PCR based 
methods (Hbl and Nhe genes), and by cytotoxicity assays.110 If a 
probiotic strain under investigation belongs to a  bacterial genus 
where pathogenic species are known, then it is important to 
 demonstrate the absence of associated virulence factors.
another, suggesting that several companies are using  duplicate 
cultures of the same probiotic strain. Furthermore, some human 
isolates were indistinguishable from a particular probiotic strain, 
suggesting that some of these isolates may be re-isolations of com-
mercial strains that display a high genotypic stability. Likewise, 
a study of probiotic products claimed to contain bifidobacteria 
revealed that the number of genotypically unique Bifidobacterium 
strains used as commercial probiotics was surprisingly low in 
view of the great range of products  analyzed.107 Among a set of 
39 B. animalis subsp. lactis isolates recovered from 32 different 
products, only four strain types could be distinguished by PFGE. 
The large majority of these products (n = 30) were found to con-
tain PFGE type I, thus indicating that a single strain exhibit-
ing a highly stable PFGE fingerprint was used in a broad range 
of dairy-based and lyophilized probiotic products worldwide. 
Besides their relevance in the scope of microbial product quality 
or epidemiological surveys, the findings shown in these studies 
indirectly suggest that Lactobacillus and Bifidobacterium strains 
used in probiotic applications tend to show a high genotypic sta-
bility under different production and/or host passage conditions. 
Clearly, more direct and in-depth evidence for this hypothesis 
needs to be gathered from long-term studies for commonly used 
probiotic strains, ideally using a series of different molecular typ-
ing methods or, ultimately, comparative genomics. Complete 
genome sequencing of Lactobacillus delbrueckii subsp. bulgaricus, 
a LAB member applied worldwide in yogurt production, revealed 
that the genome of this organism is in a phase of rapid reductive 
evolution as a possible result of its adaptation from a plant-associ-
ated habitat to a milk environment through the loss of superflu-
ous functions and protocooperation with S. thermophilus.132 In 
the same way, comparative genomics could also determine the 
potential of probiotic strains to acquire and/or transfer DNA ele-
ments during host passage and long-term colonization, which is a 
research area that has remained virtually unexplored.
Viability. One challenge faced by the probiotic 
 manufacturing industry is the delivery of live, viable micro-
organisms. Maintaining viability is related to physiological 
 characteristics of the strain as well as delivery format. For 
example, dairy products have an inherently shorter shelf-life 
than freeze-dried probiotic products in the form of powders 
and pills. Even within dried formats, levels of oxygen, mois-
ture and storage temperature play an important role in stability. 
Inactivated microbes, although not considered probiotics, have 
been investigated for beneficial effects and were considered to 
be a possible solution to overcome stability problems. But live, 
viable probiotics appear to have superior efficacy to heat-inac-
tivated microbes for both in vitro and clinical studies, largely 
dispelling this notion.32,133,134 However, it should be recognized 
that the presence of dead or injured microbes in commercial 
products is unavoidable, as some death occurs during storage of 
products and the standard approach to maintaining the target 
dosage of live probiotic entails addition of surplus probiotics to 
account for any death occurring during storage.
Interestingly, some studies have revealed adverse effects 
 resulting from ingestion of heat-killed probiotics. In a study 
comparing one group that ingested live, viable L. rhamnosus 
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can be mistaken for allergic reactions due to the similarity of 
the signs and symptoms including facial flushing, sweating, 
rash, burning taste in the mouth, diarrhea and cramps with 
severe reactions including respiratory distress, swelling of the 
tongue and throat and blurred vision.150 One of the better-rec-
ognized presentations is that of ingestion of fish from the fam-
ily Scombridae (tuna) although the accumulation of histamine 
and adverse events can be prevented through constant cool tem-
perature control.150 Although some species of Lactobacillus are 
capable of forming biogenic amines, there is great variability in 
this ability. The addition of probiotic organisms to foods should 
take biogenic amine producing capacity into account if oppor-
tunity for production and substrate availability are conducive 
to such activity.151,152 To date, there are no reported cases of 
such potentially harmful compounds found in fermented milk 
 prepared with lactobacilli.17
Presence of unlabeled microorganisms. Microbiological 
 evaluation of retail probiotic products has revealed the presence 
of microorganisms not indicated on the label.107,108,153-155 The pres-
ence of these microbes suggests either inadequate attention to pro-
duction parameters and a failure in quality control procedures, or 
an intention to deceive consumers, substituting less expensive or 
more production-friendly microbes for labeled ones, presumably 
for financial gain. Avenues for contamination of the production 
process are numerous. A commercial product that untruthfully 
labels the contents in the product is illegal. Furthermore, it is 
impossible to assess the safety of such a product as the identity of 
the strains in the product are not known or characterized.
In addition to microbiological hazards with labels that 
 inaccurately describe contents, excipients used in formulation of 
final products could also be problematic. For instance, some chil-
dren receiving probiotics have developed anaphylactic reactions 
from cow’s milk protein allergens present in the probiotic prod-
uct.156,157 There are culture methods to grow lactic acid bacteria 
that effectively eliminate residual cow milk protein allergens. 
While it is unclear whether such methods are sufficient to exempt 
products from food allergen labeling requirements, unless the 
probiotic product specifically states that it is allergen-free, allergic 
individuals who want to use probiotic products should actively 
seek assurance from manufacturers that a given product does not 
 contain an offending allergen.
Measurement of Safety:  
Limitations of Existing Models
Standard acute, subchronic and chronic oral toxicological studies 
performed with certain currently-used probiotics have not dem-
onstrated any adverse effects even at very high doses over a long 
period of time.158,159 It has proved difficult to establish infection 
after oral administration of probiotic bacteria, even when tested 
at doses 10,000 times higher than those normally consumed by 
humans.160 Adverse effects might be detected only when pushing 
the boundaries of test systems, raising the question of the very 
relevance of these systems.
Monitoring toxicity in vivo. The following are in vivo 
 measures that are of use in when evaluating toxicity in vivo.
D-lactic acid production. Human metabolism produces the 
L(+)-isomer of lactic acid. D(-)-lactate presence in humans is a 
consequence of bacterial production of D(-)-lactate directly or 
indirectly from L(+)-lactate through a bacterial DL-lactate race-
mase.141 Not all probiotic species possess the ability to directly 
produce D(-)-lactate, but some Lactobacillus species do pos-
sess the racemase enzyme and, thus, can convert L(+)-lactate to 
D(-)-lactate.142 Whereas normally lactobacilli constitute a very 
small fraction of the microbial population of the human intes-
tinal tract at all ages,143 the same is not true for those suffering 
from D-lactic acidosis. Bongaerts et al. showed that in children 
with short bowel syndrome and acidosis that the majority of fecal 
flora is lactic-acid producing lactobacilli and D-lactic acid blood 
concentrations are high at the time of symptoms.144 Human cells 
metabolize and excrete D(-)-lactate poorly with the very young 
newborn and neonate being at particular risk, due to the lack of 
full renal excretory capability and decreased barrier function of 
the intestinal tract. If excessive build-up of D(-)-lactate occurs, 
metabolic acidosis may result, the early clinical effects of which 
can be difficult to detect. While clinical cases of D-lactic acidosis 
have not been observed in healthy infants, the possibility cannot 
be excluded, particularly in light of the difficulty of diagnosis of 
sub-clinical cases.
One small study evaluated otherwise older healthy infants and 
the safety of ingesting a probiotic capable of D(-)-lactate produc-
tion. Twenty-four six-month-old infants were randomly selected 
from a larger group of subjects receiving 108 CFU of L. reuteri 
ATCC 55730 since birth as part of a double blind, multi-center 
trial for the prevention of allergy. Comparison of blood levels of 
D(-)-lactate between those receiving placebo and the probiotic 
were similar at the six-month time age of the infants.145 Studies 
in newborns and infants younger than six months most at risk of 
this problem are lacking.
Most patients reported with D-lactic acidosis have been 
those with short gut syndrome as occurs following mesen-
teric thrombosis, mid-gut volvulus or Crohn’s disease.146,147 
Administration of probiotics to such individuals has been asso-
ciated with the development of D-lactic acid associated enceph-
alopathy.148 Other patients who have developed this problem 
include those who have undergone intestinal bypass surgery 
and patients with small-bowel bacterial overgrowth.146,147 One 
common feature among these patients is excessive carbohydrate 
exposure to D(-)-lactate producing bacteria. For patients devel-
oping this D-lactic acidosis, re-colonization with bacteria that 
are not D(-)-lactate producers has proven beneficial.149 Taken 
together, administration of D(-)-lactate producing probiotics 
should be carefully considered in patients at risk of developing 
D-lactic acidosis, such as those with previous bowel surgery and 
subsequent short gut syndrome and in the very young newborn 
or neonate until appropriate safety data become available for 
specific probiotic strains.
Biogenic amine production. Biogenic amines such as 
 histamine and tyramine are low molecular weight organic mol-
ecules that are present in many foods but also produced in high 
amounts by microorganisms through the activity of amino acid 
decarboxylases. Ingestion of high amounts of biogenic amines 
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opposed to a virulence factor of pathogens remains to be further 
investigated.
In vitro evaluation of the nitric oxide pathway. It has been 
suggested that nitric oxide and related reactive nitrogen inter-
mediates exert bacteriostatic and microbiocidal effects and play 
an important role in the killing of bacteria by macrophages.166 
As resistance to this pathway is thought to allow the bacteria to 
escape the phagocytic activity of innate immunity,137 this ability 
should also be assessed.
Routes of administration in the safety assessment of probiotics. The 
route of administration may play a major role in safety assessment 
of probiotics. Indeed, it was shown that mice treated orally with 
5 x 108 CFU L. salivarius CECT5713/animal were healthy and 
survived daily administration after 28 days. Yet intraperitoneal 
administration caused a significant translocation of the bacte-
ria to the liver and spleen, a transient inflammatory process, but 
without any behavioral changes, and no illness or death observed 
in the injected mice.160 In contrast, experimental sepsis following 
intraperitoneal administration of the same dose of a pathogenic 
strain of E. coli was lethal to mice at 2 days after inoculation.167 
Oral administration of probiotics appeared to be by far the safest 
route and outlined the very low infectivity of LAB and absence of 
safety issues for current uses in healthy populations.
Animal models for infectivity. Due to the low pathogenicity of 
the Lactobacillus genus, specialized in vitro and/or animal mod-
els are needed for the assessment of potential infectivity. One 
approach is to consider pushing the animal models beyond their 
normal physiological states (for example, immunosuppressed or 
severely debilitated hosts, and by using unusual routes of admin-
istration) to allow the detection of any potential pathogenicity 
of the candidate probiotic strain. Although various animal mod-
els are available, few have been reviewed and validated for the 
purposes of the safety assessment of probiotics. Animal models 
that have been reviewed for this purpose in the European Union 
PROSAFE project were the experimental endocarditis rat and 
immunocompromised mouse models.168
The rat model of experimental endocarditis is of interest 
because it is generally well accepted and shown to mimic the 
human pathophysiology of infective endocarditis.169 Thus, this 
animal model may serve as a standard for the assessment of the 
infectivity potency of a new probiotic strain, as results can be 
compared to reference negative and positive controls.170 One 
such negative control could be the poorly infective L. lactis.105 In 
this model it was shown that lactobacilli were between 100 and 
10,000-fold less infective than the two most common endocardi-
tis pathogens (Staphylococcus aureus and Streptococcus viridans) in 
human pathology.105,170 In addition, for a particular Lactobacillus 
strain, infectivity could be different between clinical and pro-
biotic isolates,14,168 but no specific causal characteristic has been 
identified. In addition, the usefulness of this type of model has 
been questioned since the clinical cases of endocarditis associ-
ated with LAB are so rare.105 A rabbit model to evaluate if a pro-
biotic can cause infectious endocarditis has also been used and 
could be considered as a possible alternative animal model for the 
e valuation of infectivity.137
Evaluation of general health status of the animals during the 
in-life phase. Any possible infection-induced changes in physi-
ological functions could be evaluated by measurements of 
blood parameters such as blood cell counts (leukocytes and red 
cells, absolute and differential), and also hemato-biochemistry 
markers such as glucose concentration and glutamic-oxalacetic 
transaminase activity. Serum α-amyloid protein can be used as 
a plasma marker of sepsis.160 C-reactive protein could also be 
measured as a general indicator of inflammation.161 However, 
serum α-amyloid protein and C-reactive protein are probably 
best-suited for murine models. Plasma malondialdehide concen-
tration could also be determined in order to evaluate changes in 
lipid peroxidation, following an oxidative stress subsequent to 
bacteraemia.160,162 This latter analysis can also be carried out at 
the end of the in-life phase.
Blood cultures for assessment of bacterial translocation. The pres-
ence of administered probiotics in blood culture (as measured 
by culturing and/or PCR-based methods) is of clinical relevance 
as an indicator of potential translocation and bacteraemia.4,161 In 
animal models, this analysis could also be carried out at the end 
of the in-life phase. This could be done in liver, spleen, blood 
and/or other potential target organs/tissues. Sampling of tissues 
or organs should be carried out carefully and in sterile conditions 
to avoid undesired cross-contamination. Detection of the admin-
istered probiotic directly from a human study subject (or patient), 
is also an important finding. Such detection requires availability 
of reliable methods for culture and identification (e.g., by PCR) 
of the organism from blood, stool and any other clinical samples 
appropriate for the study. However, such methods (such as meth-
ods for recovery of fastidious anaerobic probiotic bacteria) are not 
necessarily available in clinical laboratory settings.
Splenic weight index. This index is a ratio of the spleen weight 
to the body weight of the animal and follows a curvilinear pro-
gression. Alterations of the splenic weight index could be used as 
indicators of infections, and comparisons should be carried out 
between groups of equal body weights and between animal of the 
same gender.163
Weight-to-length ratio. A change in the weight-to-length ratio 
of the intestine could be a sign of intestinal inflammation.160 
Used alone, the clinical relevance of this parameter is rather lim-
ited, and an assessment of the weight-to-length ratio in the intes-
tine should be complemented by a macroscopic examination at 
necropsy, followed by a subsequent histopathology evaluation.
Additional markers. Total liver glutathione concentration 
and plasma malondialdehide concentration could be deter-
mined in order to evaluate changes in the antioxidant defence 
and lipid peroxidation, respectively, as a possible consequence of 
bacteraemia.160,162 Serum lactate and fecal calprotectin as a bio-
marker for intestinal inflammation164 could also be considered 
satisfactory indicators of general health status.
Measuring infectivity in vitro or in animal models. Adhesion. 
Pathogens often have a high affinity for proteins such as colla-
gen, fibrinogen and mucus, as these give them access to host tis-
sues.165 However, discriminating between mucosal adhesion as a 
normal feature of probiotics or commensal microorganisms as 
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developmental toxicity testing, it is likely worth investigating 
whether a probiotic organism becomes a permanent resident of 
the adult microbiota of the offspring. This would be particularly 
relevant to strains isolated from other species that might have 
properties that allow them to displace, for better or for worse, 
strains ordinarily present during the crucial initial developmental 
stages following birth. This would require a sensitive, practical 
and reliable method for probing for the introduced strain and 
assumes that the animal being used is a reliable model for the 
target microbial location. Given the specificity of the symbiotic 
interactions between the microbial strains and the host, it would 
seem presumptuous to assume equivalent safety of all members 
of a particular species when present. On the other hand, it may 
not be necessary to include some of the usual endpoints of repro-
ductive and developmental testing, such as teratology and male 
reproductive effects, based on theoretical grounds. The proper 
design and conduct of a reproductive and developmental toxicity 
evaluation of a probiotic proposed for widespread use as a food or 
drug is clearly a topic ripe for further discussion.
The pig as a model for assessing probiotic safety: direct 
 evidence for validation. Animal testing is a key part of evaluat-
ing the safety of anything that is intended for administration to 
humans, but it is most desirable that the animal model be selected 
with an eye to the ability to predict human response from the 
animal’s response. In the assessment of the safety of chemical 
substances, it is common to perform comparative pharmacoki-
netic studies to determine the similarity of the absorption, distri-
bution, metabolism and excretion of the substance in the chosen 
animal model and in humans. The validity of animal models is 
no less important with probiotics and prebiotics as with other 
substances, but the approach differs because the key site of activ-
ity is the gastrointestinal tract itself while for most chemicals the 
real safety issues arise after absorption. Similarity of gastrointesti-
nal morphology, physiology, permeability, microbiome and met-
abolic processes are paramount in assuring a valid animal model 
for probiotics and prebiotics. It is important to clearly define host 
characteristics in different compartments of the gastrointestinal 
tract as well as systemic responses.175,176
The pig provides unique features as an animal model for such 
research because of the resemblance to human digestive physiol-
ogy and associated metabolic processes.177 Pigs eat an omnivorous 
diet and the developmental period, especially during infancy, is 
similar to that of humans.178 Emergence of new data using novel 
molecular technologies to evaluate the intestinal microbiome 
supports the similarity between representative bacterial orders in 
the pig and humans.179
In vivo studies using pigs fed B. animalis subsp. lactis Bb-12 
starting from birth showed persistence of Bb-12 in the intestinal 
tract with daily feeding of 1010 CFU of the probiotic without clin-
ically detectable effects on health status. In addition, pigs born 
to sows fed Bb-12 during the last trimester of gestation and fed 
Bb-12 from birth were also clinically normal but showed enhanced 
upregulation of innate immunity markers.180 Effective coloniza-
tion of gnotobiotic pigs with L. acidophilus NCFM and induction 
of innate immune markers have also been demonstrated following 
rotavirus vaccination.181,182 L. rhamnosus GG and B. animalis subsp. 
Another animal model with potential for assessing infectivity 
might be derived from the standardized bacterial host resistance 
model using the intracellular pathogen Listeria monocytogenes as 
the challenge organism. This approach is commonly applied for 
the evaluation of potential immunotoxicity of candidate drugs.171 
By adapting this test to a candidate probiotic strain (e.g., a 
Lactobacillus) either through direct injection into the tail vein 
or into the peritoneal cavity, one might overcome the naturally 
poor infectivity inherent to the Lactobacillus genus. This poor 
infectivity might be also overcome by immunosuppressing the 
animals (e.g., with cyclosporine A)172 prior to using Lactobacillus 
as the challenge organism. In this bacterial host resistance model, 
implementing ex vivo evaluations of resistance to intracellular 
killing by elicited mouse macrophages could be an additional 
testing option for assessment of potential effects on innate 
immunity.137 However, none of these models are validated and 
implementation to assess safety is likely premature.105 One can 
also envisage pushing this bacterial host resistance model beyond 
normal physiological limits by using immunosuppressed animals 
and Lactobacillus as the challenge organism: immunosuppres-
sion could be achieved by injections of cyclosporine A (with a 
dose of 50 mg/kg BW/day172). In this model, implementing ex 
vivo evaluations of resistance to intracellular killing by elicited 
mouse macrophages could be an additional testing option for 
assessment of potential effects on innate immunity.137 However, 
these models are not validated and the PROSAFE conclusion 
considered that implementation of such models for safety issues 
is premature.105
Reproductive and developmental toxicity. Reproductive and 
developmental toxicity testing is a routine part of the evaluation 
of most products developed for use as food or drugs, but is rarely 
discussed for probiotics. Recent advances in understanding the 
role of the microbiota in the development of the digestive tract 
suggest that manipulation of the microbial population could 
have intentional or unintentional effects on development when 
administered to pregnant women or infants, especially before 
weaning. As more sophisticated strategies for manipulation of 
human health using microorganisms are developed, especially 
when strains beyond those found traditionally in dairy fermenta-
tions and other sources of routine human inoculation are intro-
duced in large amounts, it becomes more important to develop 
tools to gauge the broad effects of these new exposures.
Guidelines for reproductive and developmental testing include 
the Organization of Economic Cooperation and Development 
(OECD) guidelines that are reflected in national173 and interna-
tional guidance documents.174 These tests are capable of detect-
ing disruptions in digestive function manifested by monitoring 
generic signs of health status such as low survival or birth weight 
of pups, slower growth or development of pups or major histo-
logical disruptions in specific organs such as the intestinal walls. 
Reproductive toxicity studies most frequently employ mice, rats 
and rabbits, although dogs or pigs can be used based on the spe-
cific needs of the evaluation.
Guidelines such as those cited above are meant to be flexible 
and need to be adapted to those questions that are relevant to 
the probiotic being tested. In addition to the usual endpoints of 
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four steps: (1) definition of the taxonomy of the microbe; (2) col-
lection of sufficient information providing the basis for QPS status, 
including any scientific literature, history of use, industrial appli-
cations, ecological data and human intervention data; (3) exclu-
sion of pathogenicity; and (4) definition of the end use. If there are 
no safety concerns for a certain taxonomic group, or if any safety 
concerns have been allayed (qualification), then QPS status may 
be granted. Subsequently, a microbial strain categorically assigned 
to a QPS group would be exempt from further safety assessment, 
other than satisfying any qualifications specified. Microbes that 
are not considered suitable for QPS would remain subject to a 
full safety assessment. Members of the lactic acid bacteria, which 
include some species of probiotic bacteria, will be among the first 
groups to be evaluated. The introduction of this system appears to 
be favorably received so far and is considered by some more flex-
ible than the GRAS system used in the United States taking into 
account new emerging safety risks such as acquisition of antibiotic 
resistance and virulence determinants.193,194
PROSAFE. A European Union-funded project “Biosafety 
Evaluation of Probiotic Lactic Acid Bacteria for Human 
Consumption” (PROSAFE) had the objective to propose recom-
mendations towards an evidence-based safety assessment of probi-
otics for human use. Conclusions from this project were presented 
at a workshop in 2006,105,168 and these  recommendations were:
(1) Molecular methods, such as ribosomal DNA sequencing, 
conducted by an expert laboratory, should be used to taxonomi-
cally classify LAB.106 Moreover, the probiotic strain should be 
deposited in a public culture collection, albeit with restricted 
access.
(2) Microbes not belonging to the wild-type distributions of 
resistance levels to relevant antimicrobials should not be devel-
oped as future products for consumption by humans or animals 
in the food chain without proper risk assessment.123
(3) Use of Enterococcus probiotics or other LAB that harbor 
known and confirmed virulence genes should be avoided. The 
presence of other properties including bile acid deconjugation, 
adhesion to cell lines and extracellular matrix proteins were 
insufficiently associated with virulence, and along with survival 
of probiotics in in vitro colon models, were considered irrelevant 
for biosafety assessment.
(4) In addition to following European guidelines for in vivo 
safety assessment, human colonization should be studied in a 
randomized, placebo-controlled, double-blind design but details 
of such a study were not specified.
(5) The potential use of animal models to measure safety was 
very controversial. However, the rat model of experimental endo-
carditis was suggested as the most reliable animal model.168,169
FAO/WHO. As part of the 2002 effort to establish guidelines 
for the use of probiotics in foods, a group of experts described 
a general approach to characterization of a probiotic.103 Criteria 
considered useful for establishing safety by this group overlapped 
with the PROSAFE conclusions listed above, and included the fol-
lowing. Note that although the document advises certain assess-
ments, guidance in how to assess and how to interpret results 
from such assessments are generally absent from this document.
(1) Established history of safe use in traditional products
lactis Bb-12 have been shown to adhere to pig intestinal mucosa 
and displace or inhibit pathogenic Salmonella, Clostridium and 
Escherichia coli in vitro,183 and to ameliorate in vivo the nematode 
induced inhibition of glucose uptake without inducing any histo-
logical changes.180,184 The impact of probiotic use on prevention 
and treatment of some serious gastrointestinal diseases affecting 
neonates, including necrotizing enterocolitis185 and colitis,186 have 
also been modeled in recent studies using young pigs.
It is clear that the pig colon can be colonized with several dif-
ferent probiotic strains currently used by humans without clinical 
and local tissue abnormalities. The pig is additionally advanta-
geous because many infectious bacterial, viral, parasitic and 
fungal agents are in common with humans, and autoimmune, 
allergic and metabolic disease models have been developed. The 
availability of new immunological reagents,187 molecular tools for 
the detection of changes in immune response188 and tracking of 
changes in the microbiome in the pig gastrointestinal tract,189-191 
should facilitate the validation of safety studies.
Key Initiatives in Probiotic Safety
European Food Safety Authority (EFSA). Various initiatives 
addressing the safety of probiotics for humans have been under-
taken, in particular in the European Community. Detailed 
reviews and opinions of current practices in safety assessment 
in the European Union are published.192,193 No formal safety 
testing guidelines for food-associated microbes are established 
within the European Union. EFSA was established in 2002 to 
address the increasingly important and complex scientific and 
technical issues in relation to food and feed safety (Regulation 
No. 178/2002). Nevertheless, the exact regulatory model for 
approval of a novel probiotic microbe has remained ambiguous. 
The European Union Novel Food regulation (9258/1997 EEC), 
which encompasses novel foods and food ingredients that have not 
been used for human consumption to a significant degree within 
the Community prior to 1997, provides a regulatory framework 
for probiotics. However, probiotics that have a basis for histori-
cal use or are used as additives or processing aids fall outside the 
scope of the novel food regulation. To date no probiotic strain has 
been subjected to such a thorough safety evaluation according to 
the Novel Food regulation. In contrast to probiotics intended for 
humans, the European Union regulations concerning safety of 
microbe-based feed additives for animal agriculture follow a very 
strict procedure.192,194
Qualified presumption of safety (QPS). Since no consensus 
document existed at the time, the European Union Scientific 
Committee on Animal Nutrition published a position paper in 
2002 for safety assessment and regulatory aspects of microor-
ganisms in feed and food applications. In this document, the 
Scientific Committee on Animal Nutrition proposed an approach 
to safety known as “Qualified Presumption of Safety”.195 The sci-
entific committee to EFSA advised that QPS was a suitable system 
for a common European approach to safety of bacterial dietary 
supplements. EFSA is currently finalizing the 2008 review of QPS 
guidelines. Details of this system are available from EFSA196 and a 
general scheme is presented in Figure 1. Establishing QPS involves 
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The approach used by Health Canada for safety, efficacy and 
quality of probiotics is based on recommendations of the Joint 
FAO/WHO working group for the evaluation of probiotics in 
food103 and recommendations published by EFSA. In addition, 
unless applicants can demonstrate otherwise, efficacy, safety and 
quality will be considered based on the understanding that both 
advantageous and deleterious probiotic effects on human health 
are strain-specific.
Safety dossiers should minimally provide, for all strains in the 
formulation, evidence of safe historical use of the species, a strain-
specific literature review or in vitro characterization for each 
strain of adverse metabolic activities (for example, D-lactate pro-
duction, bile salt deconjugation, bacteriocins, enzymatic activi-
ties), identity information at both the genotypic and phenotypic 
level, strain-specific characterization of antibiotic resistance and 
justification by both literature review and assay that antibiotic 
resistance is not transferable. Alternatively, a comprehensive jus-
tification for omission of this testing would be required for each 
strain that was not tested.
United States. In the United States, the term “probiotic” is 
not legally defined at the national level. The Food and Drug 
Administration approach is to regulate probiotics using the regu-
latory structure pertinent for the intended use of the probiotic. 
Possible regulatory categories would include food, food ingre-
dient, dietary supplement or drug. Each category has specific 
standards regarding efficacy, allowable claims, safety and good 
manufacturing practices. Sanders199 provides some perspective of 
United States regulatory issues pertinent to probiotics. Recently, 
the National Institutes of Health and the United States Food and 
Drug Administration commissioned an evidence-based review of 
probiotic safety through the Agency for Health Care Quality and 
(2) Absence of a significant risk with regard to transferable 
antibiotic resistance
(3) Absence of a significant risk with regard to virulence 
properties
(4) Assessment of certain metabolic activities, such as D-lactate 
production, bile salt deconjugation
(5) Testing for toxin production if the strain under evaluation 
belongs to a species that is a known mammalian toxin producer
(6) Determination of hemolytic activity if the strain under 
evaluation belongs to a species with known hemolytic potential
(7) Assessment of side-effects during human studies
(8) Epidemiological surveillance of adverse incidents in con-
sumers (post-market)
ACE-ART. The subject of probiotics serving as potential res-
ervoirs of transferable antibiotic resistance genes was addressed in 
an European Uniion project “Assessment and Critical Evaluation 
of Antibiotic Resistance Transferability in the Food Chain” 
(ACE-ART). This project focused on non-pathogenic LAB as 
well as bifidobacteria and provided recommendations for assess-
ment and interpretation of antibiotic resistance in probiotics for 
human use.127
Health Canada: Natural health products regulations of the 
Canadian food and drugs act. Health Canada has been active 
in addressing safety, efficacy and quality issues related to pro-
biotics,197,198 and are currently developing guidance for industry 
focused on “Recommendations for the Evidence Requirements 
for Efficacy, Safety and Quality of Natural Health Products con-
taining Probiotics.” Probiotics used in food are covered under 
the Food Directorate,198 whereas probiotics (excluding genetically 
modified strains), are considered “natural health products” under 
the Natural Health Products Regulations.
Figure 1. A general scheme for the assessment of suitability for QPS status of microorganisms.196 Reprinted with permission.
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[Congressional Record, H.R. Report No. 2284, 85th Congress 
1958]) and for ingredients in dietary supplements (“reasonably 
likely to be safe” [United States Federal Food Drug and Cosmetic 
Act 21 U.S.C. 350b] and lack of “unreasonable risk of illness or 
injury under the… conditions of use” [United States Federal 
Food Drug and Cosmetic Act 21 U.S.C. 342(f)]. Closely related 
to the concept of risk is the balancing concept of benefit. There 
is widespread, perhaps universal, agreement that some level of 
anticipated benefit is an inherent part of any risk evaluation. It 
would be difficult to find support for the position that even a 
tiny deliberately imposed risk (for example, that resulting from 
voluntary addition of a substance or microorganism to a food) is 
acceptable if there is absolutely no benefit.
Application of different standards for evaluating safety can 
result in different conclusions. This is exemplified by the differ-
ence in the conclusion reached regarding the use of L. rhamno-
sus GG (LGG) in infant formula by the Norwegian Scientific 
Committee for Food Safety73 on the one hand, and the non-
governmental GRAS Expert Panel that submitted an analysis to 
the FDA on the other. The Norwegian committee found that 
“the data available are not sufficient to support the suggested ben-
eficial effects, or the safety, of LGG in infant formula…” The 
GRAS panel concluded that this intended use of L. rhamnosus 
GG was safe, and, further, that this safety was generally recog-
nized in the scientific community. The FDA did not question 
this conclusion202 of the GRAS panel, despite the fact that the 
VKM opinion had been released a year earlier.
The apparent contradiction is explained by several differences 
in the ways the VKM and the GRAS panel evaluated safety. 
Importantly, the VKM was charged with evaluating benefit, 
and then evaluating safety in light of the strength or weakness 
of the evidence for benefit. The GRAS panel conducted in the 
United States assessed only safety. Of perhaps greater importance 
is that the GRAS panel used the “reasonable certainty” stan-
dard, while the VKM determined that “our lack of knowledge 
[of long-term effects from manipulating the immune function 
of neonates] necessitates the application of precautionary prin-
ciples.” The VKM based its conclusion on both actual data (such 
as case reports of translocation) and theoretical possibilities (such 
as a possible long-term effect on the colonizing microbiota). The 
GRAS panel was equally aware of these concerns, but deter-
mined that they were sufficiently rare or unlikely as to fall under 
the level of negligible risk permitted by the “reasonable certainty” 
standard, and the FDA accepted this conclusion. This case study 
exemplifies the importance of including in any risk assessment a 
clear statement of the safety standard employed.
Conclusions
The assessment of safety of probiotics comprises consideration of 
a variety of factors:
• Record isolation history and taxonomic classification of the 
candidate probiotic
• Manufacturing controls that eliminate contamination 
(including cross-contamination between batches) of the pro-
biotic with microbes or other substances.
Research. The purpose of the project is to catalogue what is known 
about the safety of probiotics (Lactobacillus, Bifidobacterium, 
Saccharomyces, Streptococcus, Enterococcus and Bacillus) used 
in research to reduce the risk of, prevent, or treat disease. The 
literature review will assess the quality and completeness of the 
available information, and the degree of confidence to interpret 
this information. The project will provide information relevant 
to practitioners, researchers and regulators for assessing the value 
and safety of probiotic administration to reduce risk, or prevent 
or treat disease, as well as to identify priorities or needs for future 
research. The preliminary results of this review reveal that few 
publications describe research designs that systematically probe 
the safety (as opposed to the efficacy) of the probiotic. This 
review may begin the process of developing a consensus on the 
safety endpoints that are appropriate to clinical trials.
Others. In Europe, there have been several national  initiatives 
regarding safety of probiotics. The Netherlands National 
Institute of Public Health and Environment (Rijksinstituut voor 
Volksgezondheid en Milieu; RIVM) published a report with a 
scheme to consider as a basis to evaluate the safety of newly mar-
keted probiotics strains or products.200
The Norwegian Scientific Committee for Food Safety evalu-
ated the safety of the use of a specific probiotic (L. rhamnosus 
GG) to be used in infants and children 4–36 months of age.73 
The committee concluded that in the absence of convincing data 
that L. rhamnosus GG can prevent disease in this age group, and 
considering that the long-term effects on immune function are 
unknown, that there was insufficient evidence to substantiate 
safety for this use. In addition, a subcommittee of this same orga-
nization in 2009 conducted a benefit/risk assessment for the use of 
probiotics for patients in hospitals. They considered: (1)  bacterial 
translocation from the gut and infectious disease; (2) virulence 
factors including toxicity; (3) metabolic functions including host 
storage, platelet aggregation, deconjugation of bile acids and deg-
radation of mucin; and (4) resistance to antimicrobials. They 
concluded that due to reported adverse effects, probiotic bacteria 
should not be consumed by critically ill individuals.
The International Life Sciences Institute (ILSI) Europe has 
proposed a new activity on functional safety of probiotics in 
particular to address the differences between probiotics used for 
foods compared to bio-therapeutic agents to cure disease.201
In India, the government announced its intent to formulate 
guidelines for regulation of probiotic foods which would be in 
place by January 2010. A task force set up by the Indian Council of 
Medical Research is responsible for formulating the guidelines that 
in addition to product safety, would address quality and reliability.
Review of Standards for Safety  
for Foods, Supplements and Drugs
The degree of risk that is regarded as acceptable can vary depend-
ing on the standard being used to evaluate safety. There is no 
such thing as “zero risk”; in any risk assessment some element of 
uncertainty remains. Regulatory definitions or limits recognize 
these concepts. For example, risk standards in the United States 
differ for conventional foods “reasonable certainty of no harm” 
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on the topic of safety of probiotics. The workshop included 
representatives from industry, academia and government. The 
focus of this discussion was on immunological, microbiological 
and toxicological issues that must be considered when review-
ing safety of use, with special consideration given to emerg-
ing concerns and appropriateness of currently available model 
systems. The area of genetically recombinant microbes was not 
included. This paper reflects the discussion and compiles the 
conclusions that were reached.
Workshop composition. Chair : Mary Ellen Sanders (Dairy 
& Food Culture Technologies), Co-chair : James Heimbach 
(JHEIMBACH LLC), Participants: Louis Akkermans 
(University Medical Center—Utrecht), Martin Antonsson 
(Probi AB), Simon Cutting (University of London, Surrey), 
Linda Duffy (National Center for Complementary and 
Alternative Medicine, Bethesda, MD), Cara Fiore (United 
States Food and Drug Administration, Center for Biologics 
Evaluation Research), Bénédicte Flambard (Chr. Hansens), 
Dirk Haller (ZIEL - Research Centre for Nutrition and Food 
Science), Cathy Hammerman (Shaare Zedek Medical Center), 
Geert Huys (Ghent University), Mary-Anne Kent (Health 
Canada), Artem Khlebnikov (Danone Research), Dan Levy 
(United States Food and Drug Administration, Center for 
Food Safety and Applied Nutrition), David Mack (Children’s 
Hospital of eastern Ontario), Peggy Martini (Kraft Foods), 
Lorenzo Morelli (Catholic University—Piacenza), Phoukham 
Phothirath (Nestlé Research Center), Gloria Solano-Aguilar 
(United States Department of Agriculture), Michelle Sumeray 
(Wyeth Consumer Healthcare), Rob Unal (Yakult USA), Luuk 
van Duijn (Winclove), Elaine Vaughan (Unilever R&D).
• Absence of association of the probiotic with infectivity or tox-
icity, assessed at the strain level.
• Absence of transferable antibiotic resistance genes
• Physiological status of the consuming population. Special 
consideration must be made for use in vulnerable popula-
tions, including newborn infants and the critically ill.
• Dose administered
• Method of administration (oral or otherwise)
• Absences of allergenic material (for example, dairy proteins) 
for products targeted for allergic populations.
Considering all of these factors, it is paramount that it is 
recognized that a general conclusion that “probiotics are safe” 
cannot be broadly made, and such an assessment is specific to 
the many conditions indicated above. To the extent that com-
mercial probiotics are marketed as foods or dietary supple-
ments, they need to be determined to be safe for the general 
population. For drug uses (the prevention, treatment, cure or 
mitigation of disease), the safety assessment must balance risk 
with benefit. Furthermore, the pre-market assessment of safety 
should never be presumed, but must entail a considered assess-
ment of the many factors outlined here. Careful and compre-
hensive post-marketing surveillance is essential to monitor the 
occurrence of any unintended consequences, especially for use 
in vulnerable populations.
Footnote
As part of the 6th meeting of the International Scientific 
Association for Probiotics and Prebiotics held in London, 
Ontario, Canada in November 2008, a workshop was convened 
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